Wave Life Sciences (WVE) Net Income towards Common Stockholders (2014 - 2026)
Wave Life Sciences (WVE) posted Net Income towards Common Stockholders of -$26.1 million for Q1 2026, up 50.94% on a QoQ basis from -$53.2 million in Q4 2025, and up 44.35% year-over-year from -$18.1 million in Q1 2025.
Wave Life Sciences (WVE) Net Income towards Common Stockholders (2014 - 2026) Analysis & Trends
Wave Life Sciences' Net Income towards Common Stockholders history runs 13 years deep, the most recent figure standing at -$26.1 million for Q1 2026.
- Quarterly Net Income towards Common Stockholders rose 44.35% year-over-year to -$26.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$183.6 million (down 63.44% YoY) and the FY2025 annual result came in at -$204.4 million, down 110.68% from the prior year.
- Net Income towards Common Stockholders was -$26.1 million for Q1 2026 at Wave Life Sciences, up from -$53.2 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $29.3 million in Q4 2024 and bottomed at -$61.8 million in Q3 2024.
- A 5-year average of -$32.2 million and a median of -$37.8 million in 2022 frame the typical range for Net Income towards Common Stockholders.
- Peak annual rise in Net Income towards Common Stockholders reached 279.7% in 2024, while the deepest fall reached 951.9% in 2024.
- Wave Life Sciences' Net Income towards Common Stockholders stood at -$43.7 million in 2022, then surged by 62.76% to -$16.3 million in 2023, then jumped by 279.7% to $29.3 million in 2024, then plunged by 281.79% to -$53.2 million in 2025, then surged by 50.94% to -$26.1 million in 2026.
- Business Quant data shows WVE's Net Income towards Common Stockholders at -$26.1 million in Q1 2026, -$53.2 million in Q4 2025, and -$53.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -625.73 |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | -0.68 |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 472.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -453.82 Mn |
| 10 | Wave Life Sciences | 1.19 Bn | 649.41 Mn | - | -26.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -26.09 Mn |
| Dec 31, 2025 | -53.18 Mn |
| Sep 30, 2025 | -53.85 Mn |
| Jun 30, 2025 | -50.47 Mn |
| Mar 31, 2025 | -46.88 Mn |
| Dec 31, 2024 | 29.25 Mn |
| Sep 30, 2024 | -61.78 Mn |
| Jun 30, 2024 | -32.92 Mn |
| Mar 31, 2024 | -31.56 Mn |
| Dec 31, 2023 | -16.28 Mn |
| Sep 30, 2023 | 7.25 Mn |
| Jun 30, 2023 | -21.10 Mn |
| Mar 31, 2023 | -27.41 Mn |
| Dec 31, 2022 | -43.71 Mn |
| Sep 30, 2022 | -39.00 Mn |
| Jun 30, 2022 | -41.30 Mn |
| Mar 31, 2022 | -37.81 Mn |
| Dec 31, 2021 | -34.79 Mn |
| Sep 30, 2021 | -6.23 Mn |
| Jun 30, 2021 | -38.77 Mn |